九典制药总经理杨洋表示，YJ-2301项目具有鲜明创新性和良好开发前景，九典制药将发挥在药品研发、生产注册及市场推广的经验优势，全力推进项目 产业化进程，期待与学校建立长期深入的战略伙伴关系。 日前，南京医科大学教师团队与湖南九典制药（300705）股份有限公司在湖南浏阳举行YJ-2301项目转让签约仪式。据悉，本次交易总金额近4亿元，标志 着又一高校原创成果成功走向产业化。 扬子晚报/紫牛新闻记者王赟 YJ-2301作为一款小分子镇痛创新药，其核心优势在于采用全新作用机制。针对性解决现有镇痛药物普遍存在的嗜睡，多次给药耐受等副作用问题，具备 广阔的市场应用空间。相关专利已完成校内转化并获全国高校生物医药区域技术转移转化中心(江苏苏州)、苏州南医大创新中心全流程赋能。此次合作将 加速该项目后续开发与临床转化，是学校打通科研成果走向市场"最后一公里"关键举措，也为校内原始创新成果转化提供了可复制、可推广的实践范式。 通讯员朱珠 南京医科大学党委书记兰青指出，此次合作是学校深化产学研融合、加速科技成果转化的重要实践。学校始终坚守服务"健康中国"战略的初心，将以此次 合作为纽带，整合科研优势、人才资源与企业产业化能 ...

Group 1 - Company JiuDian Pharmaceutical (九典制药) announced an investment of up to 400 million yuan to acquire technology for a new analgesic drug YJ2301 from Suzhou Yuanju Pharmaceutical Technology Co., Ltd. This acquisition aims to enrich the product pipeline and promote the transformation into innovative drugs [1] - The transaction includes a milestone payment of up to 11 million yuan, with the total transfer fee not exceeding 400 million yuan, structured through milestone payments and sales commissions [1] - The YJ2301 project has completed part of its preclinical research and has submitted relevant patent applications, with the goal of enhancing the company's R&D capabilities and long-term core competitiveness [1] Group 2 - JiuDian Pharmaceutical received a drug registration certificate for Trimebutine Maleate Tablets from the National Medical Products Administration, which is used to improve symptoms of irritable bowel syndrome [2] - The sales figures for Trimebutine Maleate Tablets are projected to be 276 million yuan, 292 million yuan, and 266 million yuan for the years 2022, 2023, and 2024, respectively [2] - The company has a strong presence in the chemical drug patch market, with its two core products, Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch, ranking first in sales in public hospitals in urban and county-level areas in 2023 and 2024 [2] Group 3 - JiuDian Pharmaceutical faced increased sales pressure due to competition, with operating expenses reaching 1.229 billion yuan in the first three quarters of the year, resulting in a cost ratio of 54.20% [3] - The company reported total revenue of 2.268 billion yuan, a year-on-year increase of 5.69%, while net profit attributable to shareholders decreased by 9.64% to 406 million yuan [3] - For 2024, the company anticipates revenue of 2.931 billion yuan, an increase of 8.85%, and a net profit of 512 million yuan, reflecting a growth of 39.13% [3] Group 4 - As of the market close on December 12, JiuDian Pharmaceutical's stock price was 15.61 yuan per share, with a total market capitalization of 7.81 billion yuan [4]

Group 1 - Lu Kang Pharmaceutical plans to increase capital by 109 million yuan to its wholly-owned subsidiary Bio-Pesticide Company and 27 million yuan to Ze Run Company, aiming to expand its pesticide and sales sectors [1] - Hui Green Ecology intends to sell two properties in Ningbo for 12.52 million yuan, expecting a net profit impact of approximately 6.23 million yuan from the transaction [2] - Tianyuan Co., Ltd. plans to invest 185 million yuan in an intelligent upgrade project for its titanium dioxide production facilities [3] Group 2 - Metro Design has received approval from the Shenzhen Stock Exchange for its share issuance to acquire 100% equity of Guangzhou Metro Engineering Consulting Co., Ltd. for 511 million yuan [4] - South Network Energy announced a mid-term profit distribution plan for 2025, proposing a cash dividend of 0.07 yuan per 10 shares [5] - Qibin Group plans to establish two wholly-owned subsidiaries in Shenzhen with a registered capital of 100 million yuan each [6] Group 3 - All New Good received an administrative regulatory decision from the Shenzhen Securities Regulatory Bureau due to issues in financial accounting and information disclosure [7] - Luokai Co., Ltd. announced that its shareholders plan to reduce their holdings by up to 3% of the company's shares [8][9] - Jincheng Pharmaceutical's actual controller received an administrative penalty from the CSRC for stock manipulation, leading to the resignation of the chairman [10] Group 4 - Yicheng New Energy intends to acquire a 7.69% stake in Kaifeng Times for 10 million yuan, enhancing its strategic development [11] - Yujing Co., Ltd. signed a sales contract worth approximately 28.6 million USD with an overseas photovoltaic company [12] - Nuocheng Jianhua's TRK inhibitor, Zoltracitinib, has been approved for market entry in China [13] Group 5 - Nandu Power announced that its controlling shareholder is planning a change in control, leading to a temporary suspension of its stock [14] - Xinxing Casting plans to acquire 100% equity of China Resources Steel for 1.244 billion yuan to focus on special steel development [15] - Xinlitai is planning to issue H-shares and list on the Hong Kong Stock Exchange [16] Group 6 - Blue Fan Medical's subsidiary received approval for a new medical device, the coronary artery scoring balloon dilation catheter [18] - China Iron & Steel plans to establish a joint venture with several companies to provide new energy transportation solutions with a registered capital of 500 million yuan [19] - Jifeng Technology intends to sign a cooperation framework agreement with Dongtai Lianfei for a total transaction amount not exceeding 100 million yuan [20] Group 7 - Zhongwei Electronics announced a change in its actual controller, with stock resuming trading [21] - Weihong Co., Ltd. plans to reduce its holdings by up to 1.15% of the company's shares [22] - Te Fa Information received a criminal judgment related to a fraud case involving the acquisition of Shenzhen Te Fa Dongzhi Technology Co., Ltd. [23] Group 8 - Sunshine Dairy's controlling shareholder's concerted action plans to reduce holdings by up to 3% of the company's shares [24] - Meikailong reported that Taobao Holdings and New Retail Fund collectively reduced their H-shares by 30.616 million shares [25] - Xinjubang plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [26] Group 9 - Beite Technology's application for issuing A-shares to specific objects has been approved by the Shanghai Stock Exchange [28] - Victory Energy's controlling shareholder is planning a change in control, with stock resuming trading [29] - Jiutian Pharmaceutical signed a patent and technology transfer agreement for a small molecule analgesic drug project, with a total transfer fee not exceeding 400 million yuan [29]

格隆汇12月11日丨九典制药(300705.SZ)公布，为丰富湖南九典制药股份有限公司产品管线，提升公司 在镇痛治疗领域的技术实力与市场竞争力，推动公司创新药转型战略的落实，公司于2025年12月11日召 开第四届董事会第十六次会议，审议通过了《关于签署专利及技术转让协议的议案》，同意公司与苏州 缘聚医药科技有限公司（简称"苏州缘聚"）签署关于小分子镇痛药物YJ2301项目的《专利及技术转让协 议》，引进其相关专利及技术。本次交易转让费用总金额不超过人民币4亿元。 ...

Company Overview - JiuDian Pharmaceutical (SZ 300705) announced on December 11 that it has received a drug registration certificate from the National Medical Products Administration for its product "Malaise Acid Trimebutine Tablets" [1] - As of the announcement, JiuDian Pharmaceutical has a market capitalization of 7.8 billion yuan [1] Revenue Composition - For the first half of 2025, the revenue composition of JiuDian Pharmaceutical is as follows: - Pharmaceutical preparations account for 82.47% - Raw materials account for 7.65% - Pharmaceutical excipients account for 6.03% - Plant extracts and others account for 3.16% - Technology transfer and services account for 0.63% [1]

Core Viewpoint - JiuTian Pharmaceutical (300705.SZ) has received the drug registration certificate for Trimebutine Maleate Tablets from the National Medical Products Administration, indicating a significant step in expanding its product portfolio in the gastrointestinal treatment market [1] Group 1: Product Information - Trimebutine Maleate Tablets are indicated for the treatment of irritable bowel syndrome and gastrointestinal motility disorders, addressing symptoms such as loss of appetite, nausea, vomiting, belching, bloating, abdominal rumbling, abdominal pain, diarrhea, and constipation [1] - The drug was first approved for market release in France in 1970 and is currently available in various forms including tablets, capsules, and dry mixed suspensions in both domestic and international markets [1]

Core Viewpoint - The company, Jiutian Pharmaceutical, has received the drug registration certificate for Maleate Trimebutine Tablets from the National Medical Products Administration, indicating a significant regulatory approval for a product aimed at treating gastrointestinal disorders [1] Group 1: Product Information - Maleate Trimebutine Tablets are indicated for the treatment of irritable bowel syndrome and gastrointestinal motility disorders, addressing symptoms such as loss of appetite, nausea, vomiting, belching, bloating, abdominal rumbling, abdominal pain, diarrhea, and constipation [1] - The drug was first approved for market release in France in 1970 and is currently available in various forms, including tablets, capsules, and dry mixed suspensions, both domestically and internationally [1]

Core Viewpoint - Jiutian Pharmaceutical (300705.SZ) has received the Drug Registration Certificate from the National Medical Products Administration for its drug, Trimebutine Maleate Tablets, which is indicated for the treatment of symptoms related to irritable bowel syndrome and gastrointestinal motility disorders [1] Group 1 - The drug Trimebutine Maleate Tablets is used to improve symptoms such as loss of appetite, nausea, vomiting, belching, abdominal distension, borborygmi, abdominal pain, diarrhea, and constipation [1] - Trimebutine Maleate was first approved for marketing in France in 1970 and is currently available in various forms including tablets, capsules, and dry mixed suspensions in both domestic and international markets [1]

人民财讯12月11日电，九典制药（300705）12月11日公告，公司拟与苏州缘聚医药科技有限公司签署关 于小分子镇痛药物YJ2301项目的《专利及技术转让协议》，引进其相关专利及技术。本次交易转让费 用总金额不超过4亿元。本次引进小分子镇痛领域的先进技术与专利，是对公司现有研发管线的进一步 补充和完善。 ...

格隆汇12月11日丨九典制药(300705.SZ)公布，为丰富湖南九典制药股份有限公司产品管线，提升公司 在镇痛治疗领域的技术实力与市场竞争力，推动公司创新药转型战略的落实，公司于2025年12月11日召 开第四届董事会第十六次会议，审议通过了《关于签署专利及技术转让协议的议案》，同意公司与苏州 缘聚医药科技有限公司（简称"苏州缘聚"）签署关于小分子镇痛药物YJ2301项目的《专利及技术转让协 议》，引进其相关专利及技术。本次交易转让费用总金额不超过人民币4亿元。 ...